ClinicalTrials.gov
ClinicalTrials.gov Menu

The Influence of Amitriptyline on Learning in a Visual Discrimination Task

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01566825
Recruitment Status : Completed
First Posted : March 29, 2012
Last Update Posted : March 29, 2012
Sponsor:
Information provided by (Responsible Party):
Dieter Kunz, MD, Charite University, Berlin, Germany

Brief Summary:
The purpose of this study is to determine whether 75 mg amitriptyline affect the sleep dependent consolidation of procedural memory (visual discrimination task, Karni-Sagi-paradigm).

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Amitriptyline Drug: Placebo Not Applicable

Detailed Description:
Rapid eye movement (REM) sleep is considered critical to the consolidation of procedural memory - the memory of skills and habits. Many antidepressants strongly suppress REM sleep, however, and procedural memory consolidation has been shown to be impaired in depressed patients on antidepressant therapy. As a result, it is important to determine whether antidepressive therapy can lead to amnestic impairment. We thus investigate the effects of the anticholinergic antidepressant amitriptyline on sleep-dependent memory consolidation in 32 healthy men in a double-blind, placebo-controlled, randomized parallel-group study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: The Influence of Amitriptyline (Amitriptylin-CT 25 mg®) on Learning in a Visual Discrimination Task (Karni-Sagi-paradigm)
Study Start Date : August 2008
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Amitriptyline Drug: Amitriptyline
amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
Other Name: Saroten

Placebo Comparator: white 8 mm Lichtenstein® Drug: Placebo
placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11




Primary Outcome Measures :
  1. changes in the visual discrimination task's perception threshold [ Time Frame: The visual discrimination task's perception treshold is assessed before sleep (day 10 at 6 pm) and after sleep (day 11 at 6 pm). ]
    Improvement in this task is defined as a decrease in the perception threshold between training and retrieval testing.


Secondary Outcome Measures :
  1. amount of rapid eye movement (REM) sleep (sleep period time percentage) [ Time Frame: night from day 10 to day 11 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • male gender
  • age 18 through 40 years
  • ability to communicate effectively in German

Exclusion Criteria:

  • shift work within the past 24 months
  • any sleep disorder as measured by the Pittsburgh Sleep Quality Index
  • irregular sleep/wake patterns or extreme chronotype as measured by the Morningness-Eveningness Questionnaire
  • history of any neurologic or psychiatric disorders
  • regular medication intake within the past four weeks
  • contraindications for amitriptyline
  • abnormal electrocardiogram (ECG)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01566825


Locations
Germany
Charité - Universitätsmedizin Berlin, Department of Physiology CBF
Berlin, Germany, 10115
Sponsors and Collaborators
Dieter Kunz, MD
Investigators
Study Chair: Dieter Kunz, MD Charite University, Berlin, Germany
Principal Investigator: Dieter Kunz, MD Charite University, Berlin, Germany

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dieter Kunz, MD, Director of the Research Group Sleep Research and Clinical Chronobiology, Department of Physiology CBF, Charité - Universitätsmedizin Berlin, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT01566825     History of Changes
Other Study ID Numbers: AVDT
First Posted: March 29, 2012    Key Record Dates
Last Update Posted: March 29, 2012
Last Verified: March 2012

Keywords provided by Dieter Kunz, MD, Charite University, Berlin, Germany:
amitriptyline
sleep dependent memory consolidation

Additional relevant MeSH terms:
Amitriptyline
Amitriptyline, perphenazine drug combination
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants